CRVS
Corvus Pharmaceuticals, Inc.NASDAQHealthcare$14.69+1.80%ClosedMarket Cap: $1.23B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
18.98
P/S
0.00
EV/EBITDA
-29.02
DCF Value
$0.02
FCF Yield
-2.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-23.3%
ROA
-21.5%
ROIC
-69.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-12.2M | $-12.3M | $-0.18 | — |
| FY 2025 | $0.00 | -Infinity% | $-43.0M | $-15.3M | $-0.53 | — |
| Q3 2025 | $0.00 | NaN% | $-10.6M | $-10.2M | $-0.12 | — |
| Q2 2025 | $0.00 | NaN% | $-10.3M | $-8.0M | $-0.10 | — |
| Q1 2025 | $0.00 | NaN% | $-9.9M | $15.2M | $-0.13 | — |
| Q4 2024 | $0.00 | NaN% | $-8.1M | $-12.1M | $-0.18 | — |
| FY 2024 | $0.00 | NaN% | $-27.5M | $-62.3M | $-1.02 | — |
| Q3 2024 | $0.00 | NaN% | $-7.3M | $-40.2M | $-0.60 | — |
| Q2 2024 | $0.00 | NaN% | $-5.9M | $-4.3M | $-0.07 | — |
| Q1 2024 | $0.00 | NaN% | $-6.3M | $-5.7M | $-0.12 | — |
| Q4 2023 | $0.00 | NaN% | $-5.7M | $-6.7M | $-0.14 | — |
| FY 2023 | $0.00 | NaN% | $-23.4M | $-27.0M | $-0.56 | — |